Skip to main content
SpringerLink
Log in

The EUROPA Trial: Design, Baseline Demography and Status of the Substudies

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Background: Angiotensin-converting enzyme inhibitors do reduce both mortality and morbidity in patients with left ventricular dysfunction, recent myocardial infarction and hypertension. However, the long-term effects in patients with coronary artery disease have not been established. The EUROPA study is designed to assess the long-term (3–4 years) effects of perindopril on the reduction of cardiac events in patients with proven stable coronary artery disease but with no evidence of heart failure.

Study Design and Methods: EUROPA is a 12236 patient, randomised, double-blind, placebo-controlled and multicentre trial. EUROPA had an initial run-in period of 4 weeks during which patients received 4 and then 8 mg of perindopril daily to assess tolerance to maximum dose. This was followed by a double-blind randomisation to either perindopril or placebo. Patients were followed-up at 3 and 6 months and then 6 monthly until the last patient included in the main study completes the 3-year follow-up. EUROPA includes five sub-studies. Each of these sub-studies investigates the effects of perindopril on a different aspect of coronary artery disease: endothelial dysfunction, atherosclerosis progression or regression, diabetes mellitus, inflammation, thrombosis, neurohormonal activation. Patients are characterised genetically to assess characteristics associated with improved or unfavourable outcome. The final results of EUROPA will be available in 2002.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fennessy PA, Campbell JH, Mendelsohn FAO, et al. Angiotensin-converting enzyme inhibitors and atherosclerosis: Relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996; 23(Suppl 1): 530-32.

    Google Scholar 

  2. Curzen NP, Fox KM. Do ACE inhibitors modulate atherosclerosis? Eur Heart J 1997; 18:15 30-35.

    Google Scholar 

  3. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. Cardiovasc Pharmacol 1990; 15(Suppl 5): 656-72.

    Google Scholar 

  4. Pfeffer MA, Braunwald E, Maye LA, et al. On behalf of the SAVE investigators: Effects of captopril on mortality and morbility in patients with left ventricular dysfunction. N. Engl J Med 1992; 327: 669-77.

    PubMed  Google Scholar 

  5. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-02.

    Google Scholar 

  6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N. Engl J Med 1987; 316: 1429-35.

    Google Scholar 

  7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.

    Google Scholar 

  8. Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998; 19(Suppl J): J52-55.

    Google Scholar 

  9. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibitors (the PEACE Study design). Am J Cardiol 1998; 82: 25H-30H.

    PubMed  Google Scholar 

  10. Simoons ML, Vos J, de Feyter PJ, et al. EUROPA substudies, confirmation of pathophysiological concepts. Eur Heart J 1998; 19(Suppl J): J56-60.

    Google Scholar 

  11. McMurray J. TheACEInhibitor/Myocardial InfarctionTrials. From Clinical Trials to Clinical Practice. Beckenham, Kent: Publishing Initiatives Books, 1995.

    Google Scholar 

  12. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:6 85-91.

    Google Scholar 

  13. Pfeffer MA, Braunwald E, Moyes LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:6 69-77.

    Google Scholar 

  14. Young JB. Reduction of ischemic events with angiotensin converting enzyme inhibitors: Lessons and controversy emerging from recent clinical trials. Cardiovasc Drugs Thera 1995; 9: 89-102.

    Google Scholar 

  15. Remme WJ, Bartels GL. Antiischemic effects of converting enzyme inhibitors: Underlying mechanisms and future prospects. Eur Heart J 1995; 16(Suppl I): 87-95.

    Google Scholar 

  16. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26:6 71-77.

    Google Scholar 

  17. Brilla CG, Janiki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 5:17 71-79.

    Google Scholar 

  18. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effects of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319(2): 80-86.

    PubMed  Google Scholar 

  19. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats. Clin and Exper Hyper 1989; A11(7): 1325-50.

    Google Scholar 

  20. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-18.

    PubMed  Google Scholar 

  21. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-65.

    PubMed  Google Scholar 

  22. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanable heritable hyperlipidic rabbit. Hypertension 1990; 15: 327-31.

    PubMed  Google Scholar 

  23. Rolland PH, Charpiot P, Friggi A, et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini pigs. Am J Cardiol 1993; 71: 22E-27E.

    PubMed  Google Scholar 

  24. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993; 87: 283-90.

    PubMed  Google Scholar 

  25. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-88.

    PubMed  Google Scholar 

  26. MERCATOR (The Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR randomized, double-blind placebo controlled trial. Circulation 1992; 86: 100-10.

    Google Scholar 

  27. Texter M, Lees RS, Pitt B, et al. The Quinapril Ischemic Events Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Thera 1993; 7: 273-82.

    Google Scholar 

  28. Rakugi H, Wang DS, Dzau VJ. Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation. Circulation 1994; 90: 449-55.

    PubMed  Google Scholar 

  29. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaugham DE. Stimulation of Plasminogen activator inhibitor in vivoby infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin systems and fibrinolytic function. Circulation 1993; 87: 1969-73.

    PubMed  Google Scholar 

  30. Remme WJ, De Leeuw PW, Bootsma M, Look MP, Kruijssen DACM. Systemic neurohumoral activation and vasoconstruction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 1991; 68: 181-86.

    PubMed  Google Scholar 

  31. Remme WJ, Kruijssen DACM, Look MP, Bootsma M, De Leeuw W. Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. J Am Coll Cardiol 1994; 23: 82-91.

    PubMed  Google Scholar 

  32. Bartels L, Remme WJ, van der ENT M, Kruijkssen D. ACE inhibitors reduce myocardial ischemia through modulation of ischemia-induced catecholamine activation. Experience with perindoprilat. J Am Coll Cardiol 1993; 21(2): 19A.

    Google Scholar 

  33. Vincent M, Redmond G, Portevin B. Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme. Tetrahedron Lett 1982; 23: 77.

    Google Scholar 

  34. Suraniti S, Berrut G, Marre M, Fressinaud PH. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol 1993; 71: 28E-31E.

    PubMed  Google Scholar 

  35. Dyker AG, Grosset DG, Lees KR. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997; 28; 580-83.

    PubMed  Google Scholar 

  36. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: A placebo controlled study. Br Heart J 1991; 66: 206-11.

    PubMed  Google Scholar 

  37. Squire IB, MacFadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996; 27: 657-66.

    PubMed  Google Scholar 

  38. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-50.

    PubMed  Google Scholar 

  39. Antony I, Lerebours G, Nitenberg A. Angiotensinconverting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115-22.

    PubMed  Google Scholar 

  40. Dexler H, Kurs S, Jeserich M, Munzel T, Hornig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995; 76: 13E-18E.

    PubMed  Google Scholar 

  41. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993; 92: 2867-71.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Department, Royal Brompton Hospital, London

    Abba H. Gomma & Kim M. Fox

Authors
  1. Abba H. Gomma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim M. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomma, A.H., Fox, K.M. The EUROPA Trial: Design, Baseline Demography and Status of the Substudies. Cardiovasc Drugs Ther 15, 169–179 (2001). https://doi.org/10.1023/A:1011131130922

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011131130922

Search

Navigation